dc.date.accessioned2022-01-04T20:31:49Z
dc.date.available2022-01-04T20:31:49Z
dc.date.created2022-01-04T20:31:49Z
dc.date.issued2013
dc.identifierhttps://hdl.handle.net/20.500.12866/10692
dc.identifierhttps://doi.org/10.1371/journal.pone.0076323
dc.description.abstractObjectives: In developing nations, the use of operational parameters (OPs) in the prediction of clinical care represents a missed opportunity to enhance the care process. We modeled the impact of multiple measurements of antiretroviral treatment (ART) adherence on antiretroviral treatment outcomes in Peru. Design And Methods: Retrospective cohort study including ART naïve, non-pregnant, adults initiating therapy at Hospital Nacional Cayetano Heredia, Lima-Peru (2006-2010). Three OPs were defined: 1) Medication possession ratio (MPR): days with antiretrovirals dispensed/days on first-line therapy; 2) Laboratory monitory constancy (LMC): proportion of 6 months intervals with ≥1 viral load or CD4 reported; 3) Clinic visit constancy (CVC): proportion of 6 months intervals with ≥1 clinic visit. Three multi-variable Cox proportional hazard (PH) models (one per OP) were fit for (1) time of first-line ART persistence and (2) time to second-line virologic failure. All models were adjusted for socio-demographic, clinical and laboratory variables. Results: 856 patients were included in first-line persistence analyses, median age was 35.6 years [29.4-42.9] and most were male (624; 73%). In multivariable PH models, MPR (per 10% increase HR=0.66; 95%CI=0.61-0.71) and LMC (per 10% increase 0.83; 0.71-0.96) were associated with prolonged time on first-line therapies. Among 79 individuals included in time to second-line virologic failure analyses, MPR was the only OP independently associated with prolonged time to second-line virologic failure (per 10% increase 0.88; 0.77-0.99). Conclusions: The capture and utilization of program level parameters such as MPR can provide valuable insight into patient-level treatment outcomes.
dc.languageeng
dc.publisherPublic Library of Science
dc.relationPLoS ONE
dc.relation1932-6203
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectHumans
dc.subjectmajor clinical study
dc.subjectmedication compliance
dc.subjectpatient compliance
dc.subjectPeru
dc.subjectRisk Factors
dc.subjectHIV Infections
dc.subjectHuman immunodeficiency virus infection
dc.subjectantiretrovirus agent
dc.subjectcohort analysis
dc.subjectCD4 lymphocyte count
dc.subjectRetrospective Studies
dc.subjectretrospective study
dc.subjectarticle
dc.subjectHIV-1
dc.subjectAntiretroviral Therapy, Highly Active
dc.subjectdrug treatment failure
dc.subjectdrug withdrawal
dc.subjectTreatment Failure
dc.subjectDelivery of Health Care
dc.subjectOutcome Assessment (Health Care)
dc.subjectclinic visit constancy
dc.subjectdrug substitution
dc.subjecthealth care concepts
dc.subjectHuman immunodeficiency virus proteinase inhibitor
dc.subjectlaboratory monitoring constancy
dc.subjectmedication possession ratio
dc.subjectnonnucleoside reverse transcriptase inhibitor
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectvirus load
dc.titleMedication Possession Ratio Predicts Antiretroviral Regimens Persistence in Peru
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución